This database contains 1063 studies, archived under the term: "female"
Click here to filter this large number of results.
Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer’s disease
Straten, Guido,
Saur, Ralf,
Laske, Christoph,
Gasser, Thomas,
Annas, Peter,
Basun, Hans,
Leyhe, Thomas
Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer’s disease (AD). One possible mechanism of action might be the induction of neurotrophins. Recently, we found a significant increase of brain-derived neurotrophic factor (BDNF) serum levels in AD patients treated with lithium and a significant decrease of ADAS Cog […]
Improved language performance in Alzheimer disease following brain stimulation
Cotelli, Maria,
Calabria, Marco,
Manenti, Rosa,
Rosini, Sandra,
Zanetti, Orazio,
Cappa, Stefano F.,
Miniussi, Carlo
Objectives: Repetitive transcranial magnetic stimulation (rTMS) has been proposed as a possible treatment for the cognitive deficits associated with Alzheimer disease (AD). The aim of this study was to assess the long-term effects, on cognitive performance, of rTMS applied to the left dorsolateral prefrontal cortex (DLPFC) in AD patients.; Methods: Ten AD patients were randomly […]
Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers
Serrano-Pozo, Alberto,
Vega, Gloria L.,
Lütjohann, Dieter,
Locascio, Joseph J.,
Tennis, Marsha K.,
Deng, Amy,
Atri, Alireza,
Hyman, Bradley T.,
Irizarry, Michael C.,
Growdon, John H.
Preclinical and epidemiologic studies suggest a protective effect of statins on Alzheimer disease (AD). Experimental evidence indicates that some statins can cross the blood-brain barrier, alter brain cholesterol metabolism, and may ultimately decrease the production of amyloid-beta (Abeta) peptide. Despite these promising leads, clinical trials have yielded inconsistent results regarding the benefits of statin treatment […]
Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project
Satoh, Masayuki,
Ishikawa, Hiroyasu,
Meguro, Kenichi,
Kasuya, Masashi,
Ishii, Hiroshi,
Yamaguchi, Satoshi
Deficits in the cholinergic system are pronounced in dementia with Lewy bodies (DLB) and are more severe in patients with visual hallucinations (VHs). The aim is to identify the occipital glucose metabolism patterns by positron emission tomography (PET) and the changes following donepezil treatment. 13 DLB patients with VHs were enrolled in the study. After […]
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, Tomohiko,
Hanyu, Haruo,
Hirao, Kentaro,
Kanetaka, Hidekazu,
Sakurai, Hirofumi,
Iwamoto, Toshihiko
To test the effects of the PPAR-γ agonist pioglitazone on cognition, regional cerebral blood flow (rCBF), and plasma levels of Aβ40 and Aβ42, we conducted a 6-month, randomized, open-controlled trial in patients with mild Alzheimer disease (AD) accompanied with type II diabetes mellitus. We randomly assigned 42 patients to either the group treated with 15-30 […]
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M.,
Bell, K. L.,
Galasko, D.,
Galvin, J. E.,
Thomas, R. G.,
van Dyck, C. H.,
Aisen, P. S.
Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, […]
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S.,
Sperling, R.,
Keren, R.,
Porsteinsson, A. P.,
van Dyck, C. H.,
Tariot, P. N.,
Gilman, S.,
Arnold, D.,
Abushakra, S.,
Hernandez, C.,
Crans, G.,
Liang, E.,
Quinn, G.,
Bairu, M.,
Pastrak, A.,
Cedarbaum, J. M.
Objective: This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD).; Methods: A total of 353 patients were randomized to ELND005 (250, 1,000, or 2,000 mg) or placebo twice daily for 78 weeks. Coprimary endpoints were the […]
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD
Vigen, Cheryl L. P.,
Mack, Wendy J.,
Keefe, Richard S. E.,
Sano, Mary,
Sultzer, David L.,
Stroup, T. Scott,
Dagerman, Karen S.,
Hsiao, John K.,
Lebowitz, Barry D.,
Lyketsos, Constantine G.,
Tariot, Pierre N.,
Zheng, Ling,
Schneider, Lon S.
Objective: The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer’s disease is unclear. The authors assessed the effects of time and treatment on neuropsychological functioning during the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease study (CATIE-AD).; Method: CATIE-AD included 421 outpatients with Alzheimer’s disease and psychosis or agitated/aggressive […]
Effect of Rikkunshi-to on appetite loss found in elderly dementia patients: a preliminary study
Utumi, Yushi,
Iseki, Eizo,
Murayama, Norio,
Nozawa, Motohiro,
Kumagai, Ryo,
Matsubara, Youichiro,
Ichimiya, Yosuke,
Arai, Heii
Background: Functional gastrointestinal symptoms are frequently found in elderly dementia patients. In such a case, we attempt treatment by the administration of antidepressants or second-generation antipsychotics. However, these medications have a risk of side-effects. In the present study, we carried out oral administration of Rikkunshi-to to elderly dementia patients with appetite loss, and examined its […]